Skip to main content
. 2022 May 16;16:803163. doi: 10.3389/fnhum.2022.803163

TABLE 1.

Participant details.

Neurotypical control participants (NC) Group 1 (MRI 1) Group 2 (MRI 2)
Number 51 10
Gender (n female/n male) 31/20 7/3
Median age in years (range) 37.1 (20–75.6) 23 (20.3–28.5)
Handedness (right/left) 51/0 5/5

RpSTS glioma patients (GOI) (MRI 2) A B C

Age 25.5 41.2 19.8
Gender M F M
Handedness R L R
Clinical presentation Seizure Seizure Seizure
Tumour type OA (2) GBM (4) AA (3)
Tumour volume/cm3 60 11 97

Glioma control patients (GC) (MRI 2)

Number 16
Gender (n female/n male) 8/8
Median age in years (range) 42.6 (21.6–58.5)
Handedness (right/left) 13/3

Stroke patients (MRI 1) RpSTS damage (SOI) RpSTS preserved (SC)

Number 8 8
Gender (n female/n male) 2/6 2/6
Median age in years (range) 61.5 (45–73) 54.5 (26–72)
Handedness (right/left) 7/1 8/0
Median Years post stroke (range) 5.0 (1.9–14.2) 3.9 (0.8–15.4)

Demographic and clinical data for the different participant groups. MRI 1, imaged at location 1; MRI 2, imaged at location 2. Gender F, female; M, male. Handedness R, right; L, left. Tumour type (with WHO histological grading in brackets): OA, oligoastrocytoma; GBM, glioblastoma; AA, anaplastic astrocytoma (based upon the 2016 criteria; Louis et al., 2016). Tumour volume is in cm3 with measurement performed using manual segmentation in ITK-SNAP 3.6.0 (Yushkevich et al., 2006) by a neuroradiologist (author A.K.Y.).